周五盘中,诺瓦瓦克斯医药(NVAX) 股价大涨14.73%,引发市场广泛关注。据报道,推动该股大涨的主因是一家分析师机构给予诺瓦瓦克斯医药"买入"评级,目标价高达19美元。
截止当日收盘,诺瓦瓦克斯医药股价报收于7.765美元,较前一交易日大涨14.73%。全天振幅达3.82%,成交量28.26万股,换手率0.18%。
诺瓦瓦克斯医药是一家致力于研发疫苗的生物技术公司,主要产品包括针对多种传染病的新型疫苗。资料显示,该公司在欧洲市场获得最大收入。分析师看好该股,认为公司有望从欧洲持续扩张业务,而此前"买入"评级显然给予市场极大信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.